Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused
on rare diseases that transforms real-world clinical and genetic
data into actionable information for patients, physicians, and
pharmaceutical companies, and Molecular Health, a leading company
in the field of data and computing science for precision medicine,
announced today that they will collaborate exclusively to initiate
the
Real-life data and
Innovative
Bioinformatic
Algorithms (RIBA)
project – starting with Epilepsy as the first indication. RIBA aims
to foster a unique novel precision medicine environment to
accelerate, de-risk, and improve the development of new orphan
drugs based on the combination of large real-life data sets in rare
disease with innovative big data, innovative artificial
intelligence, as well as computational algorithms and expertise.
Both companies are convinced that this strategy of merging
real-life data with a global curated biomedical knowledge, as well
as applying artificial intelligence and scientific computing will
radically change and transform biomedical research, product
development, and therapy. Additionally, it will offer
data-/computing-driven solutions to guide the highest and most
precise innovation for the new way of drug development in a modern
biopharmaceutical environment.
Prof. Arndt Rolfs, CENTOGENE Chief Executive Officer, stated,
“We are excited about this collaboration. Both companies have been
analyzing the potential interaction for an extended period of time
and are deeply convinced that now is the right time to start an
exclusive cooperation focusing on rare genetic diseases. The
complementary expertise and knowledge of both companies will allow
us to reduce the time to develop a new orphan drug by combining of
real-life data and innovative computational biomedical expertise.
CentoMD®, one of the world’s largest rare disease data
repositories, allows us to take advantage of the high quality of
the real-life data from a global cohort of more than 500,000
consented patients. The extraordinary expertise of Molecular Health
will not only speed up the identification of new targets in rare
disease, but also allow us to de-risk and accelerate the
development of new orphan drugs.”
“By starting this exciting collaboration between our companies,
we are initiating and building a unique novel model of personalized
healthcare. The combination of both companies’ data and expertise
will ultimately transform modern drug development and therapy. It
will allow for the development of better drugs with higher
specificity and safety, lower attrition rates in clinical studies,
and a faster time to market to help patients with severe diseases
worldwide through novel therapies,” said Dr. Friedrich von Bohlen,
Molecular Health Chief Executive Officer. “Together with CENTOGENE,
Molecular Health´s deep scientific, medical, and computational
expertise will lay the fundament for personalized healthcare
options in rare diseases to fulfill the promise of precision
medicine.”The companies have agreed to start with Epilepsy as the
first indication. Financial details were not disclosed.
About CENTOGENE
CENTOGENE engages in diagnosis and research around rare diseases
transforming real-world clinical and genetic data into actionable
information for patients, physicians, and pharmaceutical companies.
Our goal is to bring rationality to treatment decisions and to
accelerate the development of new orphan drugs by using our
extensive rare disease knowledge, including epidemiological and
clinical data, as well as innovative biomarkers. CENTOGENE has
developed a global proprietary rare disease platform based on our
real-world data repository with approximately 3.0 billion weighted
data points from over 530,000 patients representing over 120
different countries as of March 31, 2020.
The Company’s platform includes epidemiologic, phenotypic, and
genetic data that reflects a global population, and also a biobank
of these patients’ blood samples. CENTOGENE believes this
represents the only platform that comprehensively analyzes
multi-level data to improve the understanding of rare hereditary
diseases, which can aid in the identification of patients and
improve our pharmaceutical partners’ ability to bring orphan drugs
to the market. As of March 31, 2020, the Company collaborated with
39 pharmaceutical partners covering over 45 different rare
diseases.
About Molecular Health
Molecular Health is a data science-focused artificial
intelligence computing company enabling and improving decision
making in precision medicine for healthcare organizations. The
company offerings are based on the capture, curation, integration,
and analysis of large biomedical and drug data sets and combining
them with novel artificial intelligence and machine learning
(AI/ML) technologies.
For more than a decade, the company has been developing Dataome,
a unique high-quality curated, interoperable system that combines
clinico-molecular and drug data with proprietary analytical
processes. Dataome – stand alone or in combination with customer
data – enables the unlocking of actionable intelligence at the
molecular level to a) improve diagnosis and therapy decisions by
physicians and patients; b) enrich and support better drug
discovery, drug development, trial optimization, drug
differentiation and positioning for pharma and healthcare
organizations; and c) more accurately predict the likelihood of
success and likelihood of approval of drug candidates in clinical
development for better trial prioritization and resource and
investment allocation. For more information, visit
www.molecularhealth.com.
Important Notice and Disclaimer
This press release contains statements that constitute “forward
looking statements” as that term is defined in the United States
Private Securities Litigation Reform Act of 1995, including
statements that express the Company’s opinions, expectations,
beliefs, plans, objectives, assumptions or projections regarding
future events or future results, in contrast with statements that
reflect historical facts. Examples include discussion of our
strategies, financing plans, growth opportunities and market
growth. In some cases, you can identify such forward-looking
statements by terminology such as “anticipate,” “intend,”
“believe,” “estimate,” “plan,” “seek,” “project” or “expect,”
“may,” “will,” “would,” “could” or “should,” the negative of these
terms or similar expressions. Forward looking statements are based
on management’s current beliefs and assumptions and on information
currently available to the Company. However, these forward-looking
statements are not a guarantee of our performance, and you should
not place undue reliance on such statements. Forward-looking
statements are subject to many risks, uncertainties and other
variable circumstances, such as negative worldwide economic
conditions and ongoing instability and volatility in the worldwide
financial markets, the effects of the COVID-19 pandemic on our
business and results of operations, possible changes in current and
proposed legislation, regulations and governmental policies,
pressures from increasing competition and consolidation in our
industry, the expense and uncertainty of regulatory approval,
including from the U.S. Food and Drug Administration, our reliance
on third parties and collaboration partners, including our ability
to manage growth and enter into new client relationships, our
dependency on the rare disease industry, our ability to manage
international expansion, our reliance on key personnel, our
reliance on intellectual property protection, fluctuations of our
operating results due to the effect of exchange rates or other
factors. Such risks and uncertainties may cause the statements to
be inaccurate and readers are cautioned not to place undue reliance
on such statements. Many of these risks are outside of the
Company’s control and could cause its actual results to differ
materially from those it thought would occur. The forward-looking
statements included in this press release are made only as of the
date hereof. The Company does not undertake, and specifically
declines, any obligation to update any such statements or to
publicly announce the results of any revisions to any such
statements to reflect future events or developments, except as
required by law.
For further information, please refer to the Risk Factors
section in our Annual Report for the year ended December 31, 2019
on Form 20-F filed with the SEC on April 23, 2020 and other current
reports and documents filed with the U.S. Securities and Exchange
Commission (SEC). You may get these documents by visiting EDGAR on
the SEC website at www.sec.gov.
Media Contact:
CENTOGENE
Melissa Hall
Corporate Communications
press@centogene.com
Molecular Health GmbH
Thomas König
Head of Communications & PR
media@molecularhealth.com
FTI Consulting
Bridie Lawlor
+1.917.929.5684
bridie.lawlor@fticonsulting.com
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Sep 2023 to Sep 2024